The syngo Virtual Cockpit platform reportedly enables remote access and image acquisition for CT, MRI and positron emission tomography (PET), and facilitates clinician collaboration across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may help facilitate improved access to advanced imaging for patients in remote locations.
The syngo Virtual Cockpit enables remote access for computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission CT (SPECT) imaging, according to Siemens Healthineers, the manufacturer of the software. The company said the remote platform also features live video and chat functionalities to foster collaboration between clinicians across multiple sites.
In addition to possibly facilitating improved standardization for imaging of remote patients, Siemens Healthineers suggested the syngo Virtual Cockpit could be utilized in training staff at remote facilities.
“This FDA clearance means that our customers can use syngo Virtual Cockpit for their remote scanning operations with even more confidence that they are using a proven solution — one that prioritizes patient safety and convenience while also addressing operational and staffing challenges,” noted Peter Shen, head of digital and automation at Siemens Healthineers North America.
Can a CT-Based Radiomics Model Bolster Detection of Malignant Thyroid Nodules?
May 3rd 2024A computed tomography (CT)-based radiomics model that includes 28 radiomic features showed significantly higher accuracy, sensitivity, and specificity than conventional CT in differentiating benign and malignant thyroid nodules, according to newly published research.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.